Use Hydrocortisone for Your Patient
In a 70-year-old man with acute decompensated liver failure, probable sepsis, and vasopressor-dependent shock on norepinephrine, you should use hydrocortisone at a dose of less than 400 mg/day intravenously for at least 3 days. 1
Rationale for Steroid Use in This Clinical Context
Your patient meets the criteria for septic shock requiring corticosteroid therapy based on multiple factors:
- Vasopressor dependency: Already on norepinephrine infusion, indicating shock not responsive to fluid resuscitation alone
- High mortality risk: Combination of liver failure and septic shock carries extremely high mortality (70-100%) 2
- Relative adrenal insufficiency: Patients with decompensated cirrhosis frequently have inadequate cortisol response, which is further compromised during sepsis 2, 3
Specific Steroid Regimen
Hydrocortisone is the steroid of choice because:
- Most clinical trials demonstrating benefit used hydrocortisone 4
- No clear superiority of other corticosteroids has been demonstrated 1
- Network meta-analysis shows hydrocortisone (both boluses and infusions) more effectively reverses shock than methylprednisolone 1
Dosing protocol:
- Dose: 50 mg IV every 6 hours (total 200 mg/day), OR continuous infusion of 200 mg/day 1, 3
- Duration: Minimum 3 days at full dose, continue until shock resolves 1
- Maximum: Keep total dose <400 mg/day 1
Evidence Supporting This Approach
The 2017 SCCM/ESICM guidelines specifically recommend corticosteroids for septic shock not responsive to fluid and moderate-to-high dose vasopressors (>0.1 μg/kg/min norepinephrine equivalent) 1. Your patient on norepinephrine drip clearly meets this threshold.
Key benefits demonstrated:
- Shock reversal: Faster resolution of vasopressor requirement 1, 5
- Mortality reduction: 28-day mortality decreased (RR 0.90,95% CI 0.82-0.98) 5
- ICU outcomes: Reduced ICU length of stay by 1.16 days and improved SOFA scores 5
The recommendation is conditional (weak) because the mortality benefit is modest (~2% absolute reduction) and confidence intervals cross unity in some analyses 4. However, in your high-risk patient with both liver failure and septic shock, the potential mortality benefit outweighs risks 2, 3.
Special Considerations for Liver Failure
Patients with cirrhosis have unique considerations:
- Relative adrenal insufficiency is common in decompensated cirrhosis even without sepsis 2, 3
- Case reports demonstrate dramatic hemodynamic improvement with hydrocortisone in cirrhotic patients with refractory hypotension 3
- One case series showed successful treatment of ACLF with low-dose glucocorticoids plus albumin 6
Monitoring and Side Effects
Expected adverse effects to monitor:
- Hyperglycemia: Most common (RR 1.19), requiring insulin adjustment 5, 7
- Hypernatremia: Increased risk (RR 1.57), monitor sodium closely 5, 7
No increased risk of:
Critical Pitfalls to Avoid
Don't delay initiation: Start hydrocortisone now given vasopressor dependency; don't wait for ACTH stimulation test results 1, 3
Don't use high-dose short course: Avoid regimens >400 mg/day or <3 days duration—these show no benefit 1
Don't use steroids as monotherapy: Continue aggressive infection source control, appropriate antibiotics, and hemodynamic support 4, 1
Don't abruptly discontinue: Taper gradually once shock resolves to avoid rebound hypotension 3
Ensure adequate volume resuscitation first: While your patient is already receiving albumin and pressors, verify volume status is optimized 1
Albumin Continuation
Continue your albumin therapy as it serves dual purposes in this patient:
- Volume resuscitation support 8
- Maintains oncotic pressure in liver failure 8
- May have synergistic benefit with corticosteroids in ACLF 6
Note that albumin alone for septic shock resuscitation in cirrhosis has not shown clear mortality benefit over crystalloids 9, but it remains indicated for your patient's underlying liver disease complications.